Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib

NCT01908426 is registered in ClinicalTrials.gov with Exelixis as lead sponsor.

NCT NCT01908426
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01908426 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Lead sponsor
Exelixis
Phase
Phase 3
Overall status
Completed
Start date
September 26, 2013
Completion date
January 12, 2021
Enrollment
707 (actual)
Sites
104

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma